BioNTech starts Covid-19 vaccine production at new Marburg plant

BioNTech has started production of its Covid-19 vaccine from a new manufacturing site in Marburg, Germany.

At full capacity, the new installation will be able to make 750m doses of the vaccine annually, with the first distribution of vaccines from Marburg currently penciled-in for April.

Together with Pfizer, its partner in developing the vaccine, BioNTech is targeting full-year vaccine production of 2bn doses.

BioNTech's expected vaccine output in the first half of 2021 is expected to reach 250m doses.